Tower Research Capital LLC TRC Increases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Tower Research Capital LLC TRC boosted its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 142.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 12,670 shares of the biopharmaceutical company’s stock after buying an additional 7,452 shares during the period. Tower Research Capital LLC TRC’s holdings in Theravance Biopharma were worth $119,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. KLP Kapitalforvaltning AS bought a new stake in shares of Theravance Biopharma in the fourth quarter worth about $69,000. Teacher Retirement System of Texas purchased a new stake in shares of Theravance Biopharma during the 4th quarter worth approximately $103,000. Townsquare Capital LLC bought a new position in shares of Theravance Biopharma during the 4th quarter valued at approximately $136,000. SG Americas Securities LLC grew its holdings in shares of Theravance Biopharma by 21.1% in the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,349 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in Theravance Biopharma by 27.6% in the fourth quarter. Wells Fargo & Company MN now owns 21,704 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 4,695 shares during the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $11.33.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $9.90 on Friday. The firm’s 50 day simple moving average is $9.23 and its 200-day simple moving average is $9.29. Theravance Biopharma, Inc. has a one year low of $7.44 and a one year high of $10.90. The firm has a market cap of $495.01 million, a PE ratio of -9.80 and a beta of -0.10.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. Equities research analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now owns 370,038 shares in the company, valued at $3,330,342. The trade was a 1.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 6.90% of the stock is currently owned by corporate insiders.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.